An additional important trial, called DESTINY-Gastric02, is assessing patients with gastric or gastroesophageal junction adenocarcinomas that overexpress HER2 with trastuzumab deruxtecan (T-DXd), an antibody-drug combination targeting HER2. This evidence concerns the gene ERBB2 and gastroesophageal junction adenocarcinoma.